StreetInsider.com News Articles

Medicus Pharma regains Nasdaq minimum bid price compliance

Mon, 26 Oct 2026 07:30:44 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced it received written notice from Nasdaq on October 23, 2026, confirming the company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

Nasdaq determined that the closing bid price of Medicus Pharma's common shares had been at or above $1.00 per share for ten consecutive business days, from October 12 through October 23, 2026.

The company noted that it remains subject to Nasdaq's other continued listing requirements and that there is no assurance it will maintain compliance with the minimum bid price

Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mon, 26 Oct 2026 07:30:00 -0400

Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it received written notice on October 23, 2026 (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mon, 26 Oct 2026 07:30:00 -0400

Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance

Form 424B3 Medicus Pharma Ltd.

Mon, 26 Oct 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20261026/27229958.html

Form 8-K Medicus Pharma Ltd. For: Oct 20

Fri, 23 Oct 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20261023/27228617.html

Form PRE 14A Medicus Pharma Ltd. For: Dec 02

Mon, 19 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261019/27204645.html

Form 424B3 Medicus Pharma Ltd.

Fri, 16 Oct 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20261016/27198740.html

Form 8-K Medicus Pharma Ltd. For: Oct 12

Fri, 16 Oct 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20261016/27198502.html

Form SCHEDULE 13G/A Medicus Pharma Ltd. Filed by: Melani Kenneth R.

Fri, 16 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261016/27198244.html

Medicus Pharma marks three years with portfolio and financing update

Thu, 08 Oct 2026 08:04:59 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) issued a shareholder update marking its third anniversary, outlining the development status of its three therapeutic programs and disclosing that the company has raised approximately $90 million through equity and debt financing since commencing operations in October 2023.

The company's portfolio includes CD228V, an investigational antibody-drug conjugate using Pfizer's vedotin linker-payload platform targeting melanotransferrin, a protein expressed in melanoma and several other solid tumors. Medicus said CD228V's efficacy and safety profile have not been established, and no approved therapy has validated CD228 as a treatment target. The company said its initial development focus is melanoma, with

Medicus Pharma marks three years with portfolio and financing update

Thu, 08 Oct 2026 08:04:59 -0400

Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value

Thu, 08 Oct 2026 08:00:00 -0400

Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient Development

PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today provided a shareholder update celebrating its third anniversary, highlighting three years of progress, focused on execution and capital efficient drug development. The Company has advanced its transformation into a precision oncology-led biotechnology company, with a portfolio of select novel assets, anchored by CD228V, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, SkinJect for

Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value

Thu, 08 Oct 2026 08:00:00 -0400

Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient Development

Form 424B3 Medicus Pharma Ltd.

Wed, 07 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261007/27161433.html

Medicus Pharma to execute 50-to-1 reverse stock split on Oct. 12

Wed, 07 Oct 2026 16:08:22 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced a fifty-to-one consolidation of its common shares, set to take effect on October 12, 2026, with trading on The Nasdaq Capital Market beginning on a consolidated basis that same day.

The company stated the share consolidation is intended to increase the bid price of its common shares and regain compliance with Nasdaq's minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Under the consolidation, every 50 common shares issued and outstanding will be automatically exchanged for one new common share. The company's name and ticker symbol, MDCX, will remain unchanged. The consolidated shares

Medicus Pharma to execute 50-to-1 reverse stock split on Oct. 12

Wed, 07 Oct 2026 16:08:22 -0400

Form 8-K Medicus Pharma Ltd. For: Oct 07

Wed, 07 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261007/27161273.html

Medicus Pharma files new Teverelix trial protocol with FDA

Tue, 29 Sep 2026 07:31:05 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) submitted a Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration for Teverelix, its investigational GnRH antagonist, targeting advanced prostate cancer patients at increased cardiovascular risk, according to a company statement.

The proposed seamless study design would begin with approximately 80 randomized patients in a dose-optimization stage, replacing a previously FDA-cleared 40-patient open-label Phase 2b study. If predefined continuation criteria are met, approximately 528 additional patients would be enrolled, bringing the total to approximately 608 patients. Eligible patients from the initial stage would contribute to final registration analyses.

The company said the design could reduce

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Tue, 29 Sep 2026 07:30:00 -0400

Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategy

PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it has submitted an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration (“FDA”) for Teverelix®, its investigational, next generation, long-acting GnRH antagonist, in advanced prostate cancer (“APC”) patients at increased cardiovascular (“CV”) risk.

The submission is

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Tue, 29 Sep 2026 07:30:00 -0400

The submission is

Medicus Pharma shifts SkinJect focus solely to Gorlin syndrome

Mon, 21 Sep 2026 07:31:01 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced it will concentrate clinical development of its investigational SkinJect® product exclusively on patients with Gorlin syndrome, a rare autosomal dominant disease characterized by multiple basal cell carcinoma (BCC) lesions, and discontinue further development in sporadic nodular basal cell carcinoma.

The decision follows a review that included an independent commercial assessment, clinical input from Babar K. Rao, MD, FAAD, Clinical Associate Professor of Dermatology at Weill Cornell Medical College, findings from the final Phase 2 clinical study report, and feedback from the FDA's Office of Orphan Products Development (OOPD) on the company's requests for Orphan Drug

Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

Mon, 21 Sep 2026 07:30:00 -0400

Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005, NDA-enabling, Registrational Phase 2b Study in Gorlin syndrome patients and concluding further development of nodular Basal Cell Carcinoma

PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it will focus future internally sponsored clinical development of SkinJect® exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and conclude further development in sporadic/nodular basal cell carcinoma (“nBCC”).

Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

Mon, 21 Sep 2026 07:30:00 -0400

Form SCHEDULE 13D Medicus Pharma Ltd. Filed by: Bokhari Raza

Mon, 14 Sep 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260914/27058948.html

Form SCHEDULE 13D Medicus Pharma Ltd. Filed by: Bokhari Raza

Mon, 14 Sep 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260914/27058948.html